首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1087024

基因編輯的全球市場預測(2022年～2027年)

Genome Editing Market - Forecasts from 2022 to 2027

出版日期: 2022年04月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球基因編輯的市場規模，從2020年的46億400萬美元，預計到2027年達到140億5,400萬美元，以17.29％的年複合成長率成長。

活用在農業和醫療領域，全球進行研究開發，對有解決各種問題的可能性的基因編輯技術的投資增加，預計在預測期間內的市場成長激增。此外，世界各地政府對提高作物的收穫量的基因編輯利用的支援，預計也是基因編輯市場的促進因素。

本報告提供全球基因編輯市場調查，市場概要，市場促進因素和阻礙因素，各技術、用途、終端用戶、地區的分析，競爭情形，企業簡介等資訊。

Genome editing is a method of making changes in a living organism's DNA and is used for improving crop yields, diagnosing and treating diseases, and for research purposes. The research and development in genome editing have been increasing worldwide as it is being used in the agriculture and healthcare sectors. Also, the investments in genome editing have been rising as the technique is being seen to have the potential to solve various problems, which is anticipated to surge the market growth during the forecast period. Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market. Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.

The COVID-19 pandemic had a positive impact on the market as researchers developed new diagnostic tools based on CRISPR, a genome-editing technique, for diagnosing COVID-19 patients. This led to a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021. As the spread of coronavirus continues to affect the world with its new waves and variants, the pandemic is projected to have a positive impact on the genome editing market in the coming years as well.

Growing cases of cancer and other genetic disorders

The cases of cancer and other genetic disorders have been increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is anticipated to propel the growth of the genome editing market during the forecast period. NIH researchers have recently, in January 2021, found and recognized a new genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED) that causes delays in development and hinders the proper formation of heart, facial features, and brain. Such identifications of new genetic disorders also contribute to the rising cases of genetic disorders. Furthermore, cancer cases have been proliferating. According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) has increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for females. As per IARC, the number of cancer cases in Europe is projected to jump from 4.398 million in 2020 to 5.323 million in 2040, witnessing an increase of around 21%. In North America, the cases of cancer are projected to reach 3.525 million in 2040, increasing from 2.557 million in 2020, growing by nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, owing to an increasing need for better cancer treatments.

Rising investments and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country's farmers in growing better and more productive crops. The government is making research and development easier. It also aims to make the necessary measures for genome-edited products to reach safely and responsibly to the market. Furthermore, the government of China is backing the use of CRISPR, a genome-editing technique, to improve the food supply in the country. In 2017, the state-owned company of China named ChemChina acquired Syngenta, a Switzerland-based agribusiness company working with CRISPR with an extensive research and development team. China spent $43 billion on the deal, which is the largest amount ever spent by China on buying a foreign company. The investments in genome editing are expected to grow further in the coming years, along with rising research and development, and are anticipated to boost the genome editing market growth during the forecast period.

North America to dominate the global market

Geographically, the North American region is anticipated to hold a significant market share owing to the large investments being made in the region in the field of genome editing. The Asia Pacific region is anticipated to witness substantial growth due to the surging cases of genetic disorders and cancer, along with higher spending on healthcare and research. As per the data from IARC, the number of cancer cases in Asia is projected to grow by more than 59%. Furthermore, the use of CRISPR has been increasing substantially in China, which is further expected to contribute to the market growth in the Asia Pacific.

Segmentation

By Technology

CRISPR

TALEN

ZFN

Others

By Application

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

By End-User

Academic & Government Research Institutes

Biotechnology & Pharmaceutical Companies

Contract Research Organizations

By Geography

North America

USA
Canada
Mexico

South America

Brazil
Argentina
Others

Europe

Germany
France
UK
Others

Middle East and Africa

Saudi Arabia
UAE
Others

Asia Pacific

China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others

1. Introduction

1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology

2.1. Research Data
2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of End-Users
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Genome Editing Market Analysis, by Technology

5.1. Introduction
5.2. CRISPR
5.3. TALEN
5.4. ZFN
5.5. Others

6. Genome Editing Market Analysis, by Application

6.1. Introduction
6.2. Cell Line Engineering
6.3. Animal Genetic Engineering
6.4. Plant Genetic Engineering

7. Genome Editing Market Analysis, by End-User

7.1. Introduction
7.2. Academic & Government Research Institutes
7.3. Biotechnology & Pharmaceutical Companies
7.4. Contract Research Organizations

8. Genome Editing Market Analysis, by Geography

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. UK
- 8.4.4. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Taiwan
- 8.6.6. Thailand
- 8.6.7. Indonesia
- 8.6.8. Others